EMA Authorised: Envarsus (tacrolimus) — Chiesi Farmaceutici S.p.A.

View source ↗

Summary

The EMA authorised Envarsus (tacrolimus) by Chiesi Farmaceutici S.p.A. for prevention of graft rejection in organ transplantation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft Rejection
• Organ Transplantation

Drugs mentioned

• Envarsus (tacrolimus)

Snippet

Status: Authorised. Therapeutic area: Graft Rejection. MAH: Chiesi Farmaceutici S.p.A.. Decision date: 12/02/2025